Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. reports clinical-stage biotechnology developments centered on neflamapimod, an oral small-molecule drug candidate for age-related brain disorders. Company news most often covers dementia with Lewy bodies, the Phase 2b RewinD-LB trial, biomarker and MRI analyses, pharmacokinetic work, formulation and dosing disclosures, and regulatory interactions tied to later-stage development.
Updates also include financial results, grant revenue trends, investor conference presentations, shareholder voting matters, governance items, and capital-structure disclosures. CervoMed has also reported neflamapimod's inclusion in the UK EXPERTS-ALS platform for amyotrophic lateral sclerosis research.
CervoMed (NASDAQ: CRVO) reported new clinical, plasma biomarker and MRI data for neflamapimod in dementia with Lewy bodies (DLB) at AAIC 2026. New analyses from the 159‑patient Phase 2b RewinD‑LB trial link treatment benefit to “pure” DLB patients with low plasma pTau181 and adequate drug exposure, and support a 50 mg three‑times‑daily dose for planned Phase 3 studies aligned with US and European regulators.
Neflamapimod was associated with durable slowing of right basal forebrain atrophy and increased basal forebrain connectivity versus placebo. A pharmacokinetic‑pharmacodynamic analysis identified a ~4 ng/mL plasma trough threshold tied to clinical and biomarker improvements. A separate 24‑week Phase 2 study in 26 patients showed an 80 mg twice‑daily dose met primary safety, tolerability and pharmacokinetic objectives, with encouraging but open‑label clinical activity signals.
CervoMed (NASDAQ: CRVO) completed enrollment in its Phase 2a study of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), a form of frontotemporal dementia.
The 25-patient trial assesses safety, pharmacokinetics and clinical effects, with interim biomarker data to be presented at CTAD 2026 and preclinical support published in Nature Neuroscience.
CervoMed (NASDAQ: CRVO) will feature five scientific presentations at the Alzheimer’s Association International Conference (AAIC) 2026 in London, July 12-15.
Four presentations focus on neflamapimod in dementia with Lewy bodies (DLB), covering disease progression, MRI biomarkers, exposure-response, and 80 mg BID dosing, plus a new DLB goal attainment tool.
CervoMed (NASDAQ: CRVO) closed a $10 million registered direct offering of common stock priced at-the-market under Nasdaq rules. The company sold 2,500,000 shares at $4.00 per share, with H.C. Wainwright & Co. as exclusive placement agent.
CervoMed plans to use net proceeds for working capital and general corporate purposes. The securities were issued under an effective Form S-3 shelf registration statement, with a final prospectus supplement filed with the SEC.
CervoMed (NASDAQ: CRVO) entered definitive agreements for a registered direct offering of 2,500,000 common shares at $4.00 per share, priced at-the-market under Nasdaq rules.
Gross proceeds are expected to be $10 million, closing around June 22, 2026, with funds for working capital and general corporate purposes.
CervoMed (NASDAQ: CRVO) received a USPTO notice of allowance for a new U.S. patent covering use of its drug candidate neflamapimod to treat dementia with Lewy bodies (DLB) in patients without substantial Alzheimer’s-like tau pathology, or “pure DLB”.
The patent, based on biomarker-defined patients using plasma pTau or brain imaging, is expected to provide intellectual property protection into 2042, supporting CervoMed’s pure DLB treatment strategy. There are currently no approved DLB treatments in the U.S. or EU.
CervoMed (NASDAQ: CRVO), a clinical-stage biotech focused on age-related brain disorders, will join the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit.
Management will host a virtual fireside chat and one-on-one investor meetings on Monday, June 15, 2026, with a webcast available via the company’s investor section.
CervoMed (NASDAQ:CRVO) entered a definitive securities purchase agreement for a private placement expected to raise approximately $10.5 million upfront.
According to CervoMed, proceeds should extend its cash runway into Q2 2027 and support strategic partnering to advance neflamapimod into Phase 3 for dementia with Lewy bodies and other Phase 2a programs.
CervoMed (NASDAQ: CRVO) reported Q1 2026 results and clinical progress for neflamapimod across several neurodegenerative indications.
Key points include finalized Phase 3 DLB trial design, new MRI and biomarker data, a new European patent to 2040, $12.9M cash and a $8.0M quarterly net loss.
CervoMed (NASDAQ: CRVO) reported MRI analyses from the RewinD-LB Phase 2b trial showing right basal forebrain (BF) volume increased with neflamapimod (+10.9 mm3, +3.5%) versus placebo decline (–13.3 mm3, –4.2%) at week 16 (p=0.022; p=0.028 percent change). Functional connectivity (right BF→DMN) rose 46% during the extension (p=0.014) and correlated with CDR-SB improvement (p=0.027, r2=0.43). Results were blinded, validated against autopsy pathology, and CervoMed plans a Phase 3 trial in DLB subject to financing.